Keros Therapeutics CFO Keith Regnante Steps Down; Controller Annita Tanini Named Interim CFO
KROS is trading near its 52-week low of $9.69 (5.4% above the low).
Summary
Keros Therapeutics CFO Keith Regnante resigned voluntarily, effective August 3, 2026. Corporate Controller Annita Tanini will serve as interim CFO while the company searches for a permanent replacement. No disagreements were cited.
Key Events · Executive and Board Changes · KROS
-
CFO Resignation
Effective August 3, 2026, Keith Regnante resigned as CFO to pursue other opportunities. The departure was voluntary and, according to the company, not prompted by any disagreement over accounting, financial statements, or internal controls.
-
Interim CFO Appointment
Annita Tanini, who has served as Corporate Controller and VP of Finance since May 2019, was appointed interim principal financial officer and principal accounting officer, effective August 4, 2026.
-
Interim CFO Compensation
Under the terms of her agreement, Tanini will receive an annual base salary of $302,300, a target bonus of 30% of salary, and severance of six months' salary plus COBRA upon termination without cause or resignation for good reason.
-
Permanent CFO Search Underway
A search for a new permanent CFO has commenced, ushering in a period of transition for the finance leadership.
Analysis · KROS · Life Sciences
A CFO departure at a clinical-stage biotech inevitably raises questions about financial stewardship, particularly with $281.5M in cash and a runway extending into mid-2028. The company characterizes the resignation as voluntary and unrelated to any disagreement over accounting or controls, which tempers the downside signal. Still, the market will scrutinize the transition closely—even an amicable CFO exit can unsettle investors. Elevating the internal controller to interim CFO provides continuity, but the search for a permanent replacement introduces uncertainty. The compensation terms for the interim role are modest and standard, suggesting no desperation. Overall, this is a notable governance event that warrants attention without signaling a crisis.
At the time of this filing, KROS was trading at $10.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $202.1M. The 52-week trading range was $9.69 to $22.55. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.